acute%20coronary%20syndromes%20w_out%20persistent%20st-segment%20elevation
ACUTE CORONARY SYNDROMES W/OUT PERSISTENT ST-SEGMENT ELEVATION
Acute coronary syndromes refer to any constellation of clinical symptoms compatible with acute myocardial ischemia which may be life-threatening.
It encompasses unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI).
Unstable angina is the ischemic discomfort that presents without persistent ST-segment elevation on ECG and without the presence of cardiac markers in the blood.
Non-ST-segment elevation myocardial infarction is diagnosed if cardiac markers are positive with ST-segment depression or with nonspecific or normal ECGs.
The patient typically presents with ischemic-type chest pain that is severe and prolonged and may occur at rest or may be caused by less exertion than previous episodes.

Monitoring

Further Testing

  • May be performed prior to discharge or as an outpatient
  • Stress test to provoke ischemia
    • Consider evaluation of left ventricle (LV) function if ischemia is present
    • If stress test is negative and history is still suggestive of ischemic pain, may consider nuclear scan, cardiac MRI or diagnostic coronary angiogram
    • If stress test is negative and history is not suggestive of ischemic pain, alternative diagnosis should be sought
  • Treadmill ECG, stress myocardial perfusion imaging, or stress echocardiography before discharge or within 72 hours after discharge is suggested in patients with possible ACS who have normal serial ECGs and cardiac troponins
  • Treat patient appropriately
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 13 Apr 2020
A gout drug that’s been around for years reduced the risk of ischaemic cardiovascular (CV) events when given at a low dose in patients who had myocardial infarction (MI) and was cost-effective, an analysis of the COLCOT* trial has shown.
Christina Lau, 02 Jan 2020

Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.

Pearl Toh, 15 Apr 2020
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.